I
nflammation has been demonstrated to be an important risk factor for the development of cardiovascular events. [1] [2] [3] Patients with elevated white blood cell (WBC) counts have been shown to have a higher risk of developing an acute myocardial infarction (AMI) 4 -7 and to be at higher risk for adverse events during the acute setting. 7, 8 Although the mechanism responsible for these associations is unknown, several hypotheses have been postulated, including a leukocyte-mediated hypercoagulable state, 9 leukocytemediated no-reflow, 10 and indirect cardiotoxicity mediated through proinflammatory cytokines. 11 The goal of the present study was to determine the relationship between the WBC count and coronary blood flow (both epicardial and microvascular) and other angiographic characteristics in the presence of AMI to gain insight into this pathophysiology of the relation between the WBC count and AMI.
Methods
We pooled data from the Thrombolysis In Myocardial Infarction (TIMI) 10A and 10B trials for this analysis. The TIMI 10A trial was a nonrandomized, open-label, dose-escalation study of 8 ascending doses of Tenectaplase, a mutant of recombinant tissue plasminogen activator (TNK; 5, 7.5, 10, 15, 20, 30, 40 , and 50 mg IV over 5 seconds) in 113 patients. 12 TIMI 10B was an 880-patient randomized trial that compared 30, 40 and 50 mg TNK with front-loaded recombinant tissue plasminogen activator (rt-PA). 13 Angiography was performed at 60, 75, and 90 minutes after thrombolytic administration. 12, 13 Nitroglycerin (IV or SL) was administered every 15 minutes if the systolic blood pressure exceeded 110 mm Hg. 12, 13 The TIMI studies were approved by the institutional review board of each participating center, and the trial was conducted according to the principles of the Declaration of Helsinki. The WBC counts were obtained at baseline enrollment in the trial, before treatment with the study drug, and were analyzed at the clinical site. The baseline and peak creatine kinase (CK) values were available for TIMI 10B and were expressed as the ratio of the value to the upper limit of normal at the clinical site.
Angiographic Analysis Methods
The TIMI flow grade was assessed at the TIMI Angiographic Core Laboratory as previously defined. 14 To determine coronary flow as a continuous quantitative variable, the number of cineframes required for contrast medium to first reach standardized distal coronary landmarks in the infarct-related artery (the TIMI frame count) was measured with a frame counter on a cineviewer. The data presented here were converted to the most common cinefilm speed used in the United States: 30 frames/s. [15] [16] [17] [18] [19] All flow data were assessed by a single observer (C.M.G.). The optimal single-plane projection that identified the stenosis in its greatest severity with minimal foreshortening or overlapping of branches and end-diastolic frames were chosen for quantitative angiographic analysis with a previously described and validated automated edge detection algorithm. 19 The TIMI myocardial perfusion grade was assessed as previously defined. 20 
Statistical Analysis
All analyses were performed with Stata Version 6.0. 21 All continuous variable values are reported as meanϮSD. ANOVA with a Bonferroni correction for multiple corrections or multiple linear regression was used for the analysis of continuous variables. When appropriate, the 2 test or logistic regression was used for the analysis of categorical variables. Multivariate association between WBC count and 30-day congestive heart failure (CHF) was evaluated with logistic regression models. Odds ratios are reported with logistic regression models that adjust for factors that are independently associated with the outcome variable.
Results

Baseline Characteristics
The WBC count ranged from 3.5 to 75.7ϫ10 9 /L. The median WBC count was 10.4ϫ10 9 /L, and the interquartile interval was 8.4 to 12.91ϫ10 9 /L (Figure) . Smokers had a higher WBC count than nonsmokers (Table 1) . Patients with a prior AMI, prior angina, or anterior infarctions and patients previously treated with aspirin and ␤-blockers had a significantly lower WBC count. An increased WBC count was associated with an increased baseline platelet count (rϭ0.22, PϽ0.001) and an increased hematocrit (rϭ0.17, PϽ0.001). There was a trend toward a lower WBC count in patients previously treated with HMG-CoA reductase inhibitors, and only a mild trend was identified for higher WBC count to be associated with higher baseline CK levels (rϭ0.07, Pϭ0.059). There was no association between the WBC count and prior CHF, time from symptom onset to enrollment, or use of ACE inhibitors on admission. There was no association between prothrombin time, partial thromboplastin time, baseline fibrinogen, or fibrinogen levels 1 hour after thrombolytic administration.
Relationship of WBC Count to Clinical Outcomes
The mortality rate was higher in patients with a higher WBC count (Pϭ0.03) ( Table 2) . When analyzed as a continuous variable, the WBC count also tended to be higher in patients who died within 30 days (Pϭ0.2) ( Table 3 ). The development of new CHF or shock was associated with a higher WBC count (PϽ0.001) ( Tables 2 and 3 ). The development of a recurrent AMI was not related to the WBC count (Tables 2  and 3 ). The development of any of the clinical end points (death/recurrent MI/CHF/shock) occurred more frequently in patients with a higher WBC count (PϽ0.005) ( Tables 2 and 3 ).
The WBC count and the size of the infarct as measured with the maximum CK level showed a moderate but positive correlation (rϭ0.13, PϽ0.001). Because baseline CK elevations could contribute to the peak CK value, the rise in the CK after thrombolytic administration was examined separately and was also found to correlate with the WBC count (rϭ0.13, PϽ0.001). When the baseline CK before thrombolytic therapy and the rise in CK after thrombolytic therapy were both included in a multivariate model, the rise in CK after thrombolytic therapy was found to be more strongly associated with the WBC count (tϭ3.57, PϽ0.001 versus tϭ1.88,
Pϭ0.06).
In a multivariable model that controlled for TIMI flow grade, TIMI myocardial perfusion grade, anterior MI location, baseline and maximum CK level, baseline hematocrit, platelet count, ␤-blocker use, time from symptom onset to treatment, prior MI, age, sex, and smoking status, the WBC count remained independently associated with the development of new CHF and with death ( Table 4) .
Relationship of WBC Count to the Angiographic Data
Patients with a closed infarct-related artery at 90 minutes (TIMI grade 0 or 1 flow) had a higher WBC count than did patients with an open artery (11.7Ϯ5.9ϫ10 9 /L, nϭ186 versus 10.8Ϯ3.5ϫ10 9 /L, nϭ750; Pϭ0.01) ( Table 5) . Likewise, the WBC count of patients who failed to achieve patency early, by 60 minutes, was higher (11.6Ϯ4.1ϫ10 9 /L, nϭ122 versus 10.7Ϯ3.6ϫ10 9 /L, nϭ430; Pϭ0.02). This association was also observed in a multivariate model that controlled for the duration of symptoms (Pϭ0.016). There was no association between the WBC count and the corrected TIMI frame count (number of frames required for dye to reach a standardized distal landmark), percent diameter stenosis, or minimum lumen diameter. The presence of angiographically apparent thrombus was associated with a higher WBC count (11.5Ϯ5.2ϫ10
Discussion
The results of the present study confirm previous observations that relate elevated WBC count to adverse clinical outcomes in patients with acute MI and further explore the pathophysiology that underlies this relationship. Several new important observations were made. First, an elevation in WBC count was associated with a resistance to thrombolytic therapy as demonstrated by lower rates of coronary patency at both 60 and 90 minutes after the administration of thrombolytic therapy, as well as an increased thrombus burden in patients with a patent infarct-related artery. This was independent of duration of symptoms, which has also been associated with thromboresistance. Second, elevations in WBC count were associated with impaired microvascular perfusion as demonstrated by a reduction in myocardial perfusion grade. Third, elevation in WBC count was a strong predictor of the subsequent development of CHF independent of epicardial or microvascular coronary blood flow.
In the present study, an elevated WBC count was associated with reduced epicardial patency and greater thrombus formation at the site of the ruptured plaque, suggesting that an elevated WBC count may be a marker of a hypercoagulable or thromboresistant state. Several studies have documented that a systemic inflammatory response occurs in patients with AMI and that plasma from patients with AMI stimulates the expression of interleukin (IL)-1␤ and IL-8 in leukocytes. 23 The induction of monocyte procoagulant activity with either IL-6 or IL-8 has been proposed as a possible link between the inflammation and thrombosis in patients with coronary artery disease. Neumann et al 24 investigated the effects of both of these cytokines on monocyte tissue factor (TF) expression, because the assembly of TF with factor VIIa initiates the extrinsic pathway of the coagulation cascade. They found that 
WBC count values are ϫ10 9 /L. *Started Ն2 days before study drug administration.
IL-6 and IL-8 caused an increase in TF expression on the surface of monocytes, as well as a time-and dose-dependent increase in procoagulant activity. Furthermore, this increase in procoagulant activity was induced at concentrations found in peripheral blood of patients with AMI. 25 In addition to the effects of cytokines on monocyte TF expression, it has been hypothesized that the procoagulant activity of circulating leukocytes could be increased via a second mechanism. Mac-1 (CD11b-CD18), a ␤ 2 -integrin that is involved in leukocyte adhesion, also catalyzes the conversion of factor X to factor Xa and binds fibrinogen. 26 Ott et al 9 demonstrated that there was an increase in procoagulant activity in patients who underwent successful primary angioplasty for AMI and that this increase in procoagulant activity was associated with an increase in Mac-1 expression on circulating leukocytes. Finally, the adherence of activated platelets to polymorphonuclear leukocytes via Mac-1 may also play a role in thrombus formation. 27 In addition to the reduced patency and greater thrombus burden seen in patients with an elevated WBC count, these patients had poorer downstream microvascular perfusion as assessed with TIMI perfusion grade. 20 It is possible that this impaired myocardial perfusion reflects leukocyte-mediated endothelial dysfunction and microvascular plugging, as described in animal models of ischemia-reperfusion. 10,22,28 -30 Patients with an elevated WBC count were at a significantly increased risk of developing CHF. A critical issue is whether larger MIs before thrombolytic administration cause a higher WBC count or, alternatively, whether higher WBC counts cause larger infarcts after thrombolytic administration. The hypothesis that larger MIs before thrombolytic administration cause higher baseline WBC counts was not well supported; only a nonsignificant trend was identified that related the baseline CK (a surrogate of infarct size on presentation) to the WBC count, and no relationship was identified between the duration of symptoms and the WBC count. Furthermore, anterior infarcts (which were associated with larger infarcts, baseline CKs of 1.4Ϯ3.2 times upper limit of normal, nϭ280, versus 0.85Ϯ1.2 times upper limit of normal, nϭ514) were instead associated with lower baseline WBC counts. In contrast, after the administration of the thrombolytic agent, elevated WBC counts were associated with significantly higher peak CKs. Although the peak CK may reflect some contribution from the baseline CK value, it is notable that there was a stronger relationship between CK rise after thrombolytic administration (peak CK minus baseline CK, Pϭ0.0004) and the WBC count than between the baseline CK before thrombolytic administration (Pϭ0.06) and the WBC count. Even after control for the duration of symptoms, the baseline and peak CKs, epicardial and myocardial blood flows, anterior MI location, aspirin use, ␤-blocker use, age, sex, smoking status, the hematocrit, and the platelet count (to control for confounding due to hemoconcentration), the WBC count remained independently associated with the development of new CHF.
Thus, it is possible that other mechanisms may explain the increased risk for CHF experienced by patients with elevations in WBC count. Although the cause of myocyte dysfunction in CHF is probably multifactorial, accumulating evidence suggests that oxidative stress and the release of proinflammatory cytokines may play a role in the development and pathogenesis of CHF. 11 Several studies have documented that tumor necrosis factor-␣, one of the many proinflammatory cytokines produced by leukocytes, is involved in myocyte dysfunction. 30 In support of an inflammatory cause for CHF after MI, Solodky et al 31 demonstrated that the appearance of increased leukocyte adhesiveness/aggregation in the peripheral blood of patients with anterior wall MI was independently associated with increases in left ventricular end-diastolic volume. Furthermore, Anzai et al 32 found that an elevation in serum C-reactive protein early after AMI was independently associated with readmission for CHF. Cooper et al 33 assessed the predictive value of an elevated WBC count on mortality in the Studies of Left Ventricular Dysfunction (SOLVD) trial. They found that a WBC count of Ͼ7000/mm 3 was significantly associated with an increased risk of all-cause mortality, suggesting that an elevated WBC count may reflect a 
Study Limitations
There are several important limitations to the present study. First, this analysis was retrospective and as such can only identify associations rather than confirm causality. Second, we did not collect information regarding the WBC count differential, which may have contributed important additional information.
Conclusions
Elevations in WBC count on admission are associated with reduced epicardial and myocardial blood flow, thromboresistance (arteries open later and have a greater thrombus burden), and a higher incidence of new CHF, the development of which is independent of coronary blood flow and other covariates. These relationships may explain the higher mortality rates observed among AMI patients with an elevated WBC count and help to clarify the growing body of evidence that links inflammation and cardiovascular disease.
